Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00111683 | MK0457 in Patients With Leukemia (0457-003) | PHASE1 | COMPLETED | 28 | — | — | Jun 1, 2005 | May 1, 2008 | Aug 25, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| MK-0457 | EXPERIMENTAL | Participants receive MK-0457 as a continuous intravenous infusion (CIV) at assigned dose and duration |
| Name | Type | Description |
|---|---|---|
| MK0457 | DRUG | - |
Inclusion Criteria: Part 1: * Patients with relapsed/refractory acute myelogenous leukemia (AML), poor risk myelodysplastic syndrome (MDS), B-cell acute lymphocytic leukemia (ALL), myeloproliferative diseases, or chronic myelogenous leukemia (CML) in blast crisis Part 2: * Acute myelogenous leuk...